CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
CHAMPIONS ONCOLOGY, INC.
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026
$4.69−0.01 (-0.21%)
Close on Oct 19, 2026
- Market cap
- $65.18M
- P/E (TTM)
- –
- Dividend yield
- –
CHAMPIONS ONCOLOGY, INC. revenue by segment
By business segment
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Personalized Oncology Solutions (POS) | – | – | – | – | – | – | – | – | – | $1.72M | – | – |
| Consolidated | – | – | – | – | – | – | – | – | – | $15.41M | – | – |
| Translational Oncology Solutions (TOS) | – | – | – | – | – | – | – | – | – | $13.69M | – | – |
By product or service
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacology services | $57.13M | $48.59M | $47.04M | $50.71M | $46.83M | $39.47M | $31.26M | $25.48M | $18.03M | – | 96.1% | +17.6% |
| Other TOS revenue | $1.53M | $3.68M | $3.10M | $3.05M | – | – | – | – | – | – | 2.6% | -58.5% |
| TOS data license revenue | $764.00K | $4.68M | – | – | – | – | – | – | – | – | 1.3% | -83.7% |
| Personalized oncology services | – | $0 | $18.00K | $116.00K | $49.00K | $166.00K | $790.00K | $1.28M | $1.46M | – | – | – |
| Other TOS revenue | – | – | – | $3.05M | $2.23M | $1.40M | $71.00K | $306.00K | $760.00K | – | – | – |
| TOS data license revenue | – | $4.68M | $0 | – | – | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Champions Oncology's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.